Zusduri Kit
NDC Package 72493-106-03
Package Information
Zusduri (mitomycin) kits is mitomycin is used to treat various types of cancer (such as stomach/pancreas cancer). This formulation utilizes a kit delivery system. Marketed by Urogen Pharma, Inc, this product is identified by NDC 72493-106 and is authorized under FDA application NDA215793.
Identification & Billing
- RxCUI: 2719766 - mitoMYcin 40 MG Powder for Intravesical Solution
- RxCUI: 2719766 - mitomycin 40 MG Powder for Intravesical Solution
- RxCUI: 2719771 - Zusduri 40 MG Powder for Intravesical Solution
- RxCUI: 2719771 - mitomycin 40 MG Powder for Intravesical Solution [Zusduri]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72493 - Urogen Pharma, Inc
- 72493-106 - Zusduri
- 72493-106-03 - 1 KIT in 1 CARTON * 1 POWDER, FOR SOLUTION in 1 VIAL, SINGLE-DOSE (72493-104-40) * 60 mL in 1 VIAL, SINGLE-DOSE (72493-105-60)
- 72493-106 - Zusduri
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72493-106-03 identifies a specific commercial package of 1 kit in 1 carton * 1 powder, for solution in 1 vial, single-dose (72493-104-40) * 60 ml in 1 vial, single-dose (72493-105-60) of Zusduri, a human prescription drug labeled by Urogen Pharma, Inc. This kit is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Urogen Pharma, Inc on July 01, 2025. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Mitomycin is used to treat various types of cancer (such as stomach/pancreas cancer). It works by slowing or stopping the growth of cancer cells.
How is this Urogen Pharma, Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72493010603. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.